Siemens Healthineers


Testing firms are (again) back in favour

08/09/21 -"With the rise in Delta variant cases/risks in different parts of the world – especially in the US and Europe, testing firms are likely to witness re-emerging tailwinds. This has already begun ..."

Pages
72
Language
English
Published on
08/09/21
You may also be interested by these reports :
17/10/25
This quarter was strong, driven by the launch of new AI products. We were surprised by the very strong performance in North America and Europe. ...

17/10/25
Drägerwerk delivered solid preliminary Q3 2025 numbers. Revenue of €833m was up 10.1%, translating into a 370bps expansion in the EBIT margin to 6.8% ...

14/10/25
Since our last Carl Zeiss Meditec (CZM; BUY; Germany) idea kicker in June 2024, a lot has gone wrong for the German Medtech. Results weakened due to: ...

10/10/25
Key conclusions: Chinese manufacturers can produce Meta Rayban-like glasses for €25. The margin dilution impact of Meta Ray-Ban is probably lower ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO